Clinical Trial Update: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) [Phase 2]

View source ↗

Summary

This update summarizes the results of a Phase 2 randomized trial (Scleroderma Lung Study II) comparing regimens for systemic sclerosis-associated interstitial l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Cytoxan (cyclophosphamide)

Snippet

Sponsor: Michael Roth | Conditions: Scleroderma, Interstitial Lung Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-02-10